Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2022

View Archived Issues

Peptide-based radiopharmaceutical with reduced kidney and healthy tissue uptake

Therapeutic effects of 177Lu-ofatumumab in lymphoma murine model

CHM-273S peptide shows promise as antidiabetic drug in rats

Pathogenic variants in PRRX1 gene associated with craniosynostosis

HISHS-3001, a novel tri-receptor agonist with improved efficacy in diabetic mice

Merck & Co. patents new GTPase KRAS inhibitors

Peking University divulges new transcription factor PU.1 inhibitors

OR-449 differentially regulates sulfation pathway genes in ACC

Vertex Pharmaceuticals discloses new CFTR modulators

Enanta Pharmaceuticals identifies new SARS-CoV-2 3C-like proteinase inhibitors

Gossamer Bio presents Janus kinase inhibitors

TULP3 mutations cause degeneration of major organs

Combinatorial analytics identifies hundreds of precise drug repositioning opportunities

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...